Xilio TherapeuticsXLO
Market Cap: $34.2M
About: Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers).
Employees: 73
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
50% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 6
17% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 6
3% more funds holding
Funds holding: 30 [Q1] → 31 (+1) [Q2]
2% more capital invested
Capital invested by funds: $12.1M [Q1] → $12.3M (+$254K) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]
5.42% less ownership
Funds ownership: 40.73% [Q1] → 35.31% (-5.42%) [Q2]
Research analyst outlook
We haven’t received any recent analyst ratings for XLO.